Free tool
FAERS Monitor: Latisse
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022369 or its brand name (Latisse, Bimatoprost). Reports on generic versions are filed under their own applications.
Reports
11,267
Serious
1,810
16% of reports
Hospitalization
716
Death reported
132
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,432
- ocular hyperaemia1,482
- madarosis1,369
- eye irritation1,024
- eye pruritus965
- erythema of eyelid901
- eyelids pruritus482
- eye swelling481
- wrong technique in product usage process454
- wrong technique in drug usage process384
- eyelid oedema375
- inappropriate schedule of drug administration373
- dry eye368
- skin hyperpigmentation362
- eyelid irritation337
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 4 |
| 2006 | 8 |
| 2007 | 12 |
| 2008 | 21 |
| 2009 | 397 |
| 2010 | 1,527 |
| 2011 | 886 |
| 2012 | 513 |
| 2013 | 66 |
| 2014 | 95 |
| 2015 | 1,039 |
| 2016 | 1,023 |
| 2017 | 1,070 |
| 2018 | 834 |
| 2019 | 698 |
| 2020 | 635 |
| 2021 | 505 |
| 2022 | 400 |
| 2023 | 596 |
| 2024 | 394 |
| 2025 | 302 |
| 2026 | 232 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,892 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| erythema of eyelidSignal | 901 | 372.4 | 347.5 | 277,997 |
| eyelids pruritusSignal | 482 | 341.4 | 310.3 | 138,034 |
| eyelid irritationSignal | 337 | 289.5 | 258.5 | 83,649 |
| madarosisSignal | 1,369 | 249.4 | 236.5 | 298,791 |
| skin hyperpigmentationSignal | 362 | 82.0 | 74.0 | 27,697 |
| eyelid oedemaSignal | 375 | 62.2 | 56.2 | 21,804 |
| ocular hyperaemiaSignal | 1,482 | 60.1 | 57.3 | 83,630 |
| eye pruritusSignal | 965 | 55.2 | 51.9 | 49,879 |
| eye irritationSignal | 1,024 | 33.8 | 31.9 | 32,064 |
| eye swellingSignal | 481 | 24.4 | 22.4 | 10,668 |
| wrong technique in drug usage processSignal | 384 | 19.9 | 18.1 | 6,824 |
| dry eyeSignal | 368 | 13.9 | 12.5 | 4,355 |
| inappropriate schedule of drug administrationSignal | 373 | 9.8 | 8.9 | 2,946 |
| wrong technique in product usage processSignal | 454 | 4.2 | 3.8 | 1,107 |
| drug ineffectiveSignal | 2,432 | 3.4 | 3.3 | 4,502 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.